NJ-KOLMAR-KOREA
16.7.2024 15:01:28 CEST | Business Wire | Press release
Kolmar Korea (KRX: 161890) is speeding up its global expansion by appointing experts in the global cosmetics industry to its North American subsidiary. With the plan to build its second U.S. plant early next year, the company has appointed a new head for its North American operations and a Global Chief Commercial Officer (GCCO). It has also set up a strategic framework that integrates production, sales, and R&D to better penetrate the local market. This plan includes creating an R&D team for North America and appointing a new manager.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716576189/en/
Kolmar USA 2nd plant (Photo: Kolmar Korea)
Kolmar Korea announced that it has named President Yongchul Hur as CEO of Kolmar Laboratories and Kolmar USA, its North American subsidiaries. Philippe Warnery has been appointed as Global Chief Commercial Officer (GCCO), George Rivera as Chief Science Officer (CSO) of the North American subsidiary, and Managing Director Inki Park as head of the R&D Center for North America, responsible for bridging the Korean and North American markets.
The key part of the recent appointments is bringing in many people with vast experience in the global cosmetics market. This is expected to help the company enter the North American market successfully.
Yongchul Hur, the new CEO of Kolmar North American subsidiaries, brings a wealth of experience in the global ODM business, having overseen production of Kolmar Korea's skincare and makeup products. He has previously served as president of Kolmar Beijing and Kolmar Wuxi, driving significant growth in Kolmar's Chinese operations. Prior to his tenure at Kolmar Korea, he held prominent positions in the cosmetics manufacturing industry, including factory manager at Amore Pacific and CEO of Cosvision. President Hur intends to leverage his decades of industry experience to steer local business in North America.
Philippe Warnery, newly appointed as Global Chief Commercial Officer (GCCO), is an expert in the global cosmetics market. His prior roles include CEO of Intercos North America, an Italian cosmetics ODM, and President of the UK & Ireland Region and General Manager of the Canadian Affiliate at Estee Lauder. With 25 years of experience in the global cosmetics industry, spanning both brand companies and ODM companies, his extensive network is a key competitive advantage. Warnery aims to focus on securing significant sales from major global brands as well as indie brands and recruiting influencers that are gaining popularity worldwide.
George Rivera, appointed as Chief Science Officer (CSO) of Kolmar North American subsidiaries, is an expert with over 20 years of R&D experience at global cosmetics companies such as L'Oreal USA and Intercos. Most recently, he led process and technology innovation as president of Kolmar USA. CSO Rivera, in collaboration with Inki Park, head of the North American R&D Center, plans to concentrate on research and development tailored to the local market's needs.
Center Head Park, a research expert with 18 years of experience, is responsible for adapting core technologies developed at the Kolmar R&D Complex, the Kolmar Group's global R&D hub located in South Korea, to the local market. Utilizing data accumulated at the Complex, including color, formulation, and scent, Park's team will analyze the needs of overseas markets and focus on developing customized formulations.
Kolmar Korea intends to leverage this strategic hires to maximize the operational capacity of its North American production facilities, including the first U.S. plant and the second plant under construction. The company aims to achieve $100 million in sales in the next five years. To this end, it plans to aggressively expand its sales network not only in North America but also in Central and South America. Moreover, with the rising popularity of K-beauty in the U.S. market through global distribution channels such as Amazon, the company plans to actively promote ODM sales that emphasize market accessibility and logistics efficiency for small and medium-sized Korean indie brands seeking entry into the U.S. market.
A representative of Kolmar Korea stated, “This appointment underscores our commitment to gaining new momentum in the North American market by placing industry experts at the forefront. Kolmar Korea will focus on fostering growth through the synergistic collaboration of sales, production, and R&D and expanding its influence beyond North America to Europe."
Understanding the importance of the North American market, Kolmar Korea has acquired Kolmar USA (formerly known as PTP) and Kolmar Canada (formerly known as CSR) in 2016 preemptively establishing a foundation for global expansion. In 2022, Kolmar Korea acquired 100% of the ‘Kolmar’ brand trademark rights, securing exclusive rights to the brand and enabling unrestricted business operations in the U.S. and global markets. The company is expanding its sales network with the recent opening of the Kolmar Innovation Center in New Jersey, USA.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716576189/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
